COMPANY

RedHill Biopharma

Keywords: oncology gastroenterology small molecule infectious disease disease by infectious agent COVID-19 Lung Infection Cholangiocarcinoma Cholangiocarcinoma Non-resectable Perihilar Cholangiocarcinoma Extrahepatic Cholangiocarcinoma Intrahepatic Cholangiocarcinoma Traveler's Diarrhea Helicobacter Pylori Infection Dyspepsia Pulmonary Mycobacterium Avium Complex Infection Bronchiectasis Lung Diseases Covid19 Coronavirus Infections Multiple Myeloma Crohn Disease Crohn's Disease Pancreatic Cancer Protocol Specific Unspecified Adult Solid Tumor Gastroenteritis Gastritis Irritable Bowel Syndrome With Diarrhea Diffuse Large B Cell Lymphoma Kaposi Sarcoma Relapsing Remitting Multiple Sclerosis Opaganib ABC294640 Rifamycin SV MMX RHB-104 RHB-105 RHB-204 RHB-102 BEKINDA

Profile checked Oct 10, 2026

$4.0MRaised (2 yrs)19Trials (company is sponsor)

Timeline

Oct 20, 2025 Raise Private placement: $4M (total, as published), announced Oct 20, 2025. Source: SEC filing. source ↗
2024-06 Trial start Phase 2: Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years source ↗
2024-01 Trial start Phase 2: Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years source ↗
Feb 16, 2021 Trial start Phase 2/Phase 3: Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease source ↗
Dec 1, 2020 Trial start Phase 3: RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease source ↗
Aug 21, 2020 Trial start Phase 2/Phase 3: Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia source ↗
2020-08 Trial start Phase 1/Phase 2: Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen source ↗
Jul 2, 2020 Trial start Phase 2: A Study of Opaganib in Coronavirus Disease 2019 Pneumonia source ↗
Mar 7, 2018 Trial start Phase 2: A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma source ↗
Jun 18, 2017 Trial start Phase 3: ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator source ↗
Mar 18, 2017 Trial start Phase 3: Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease source ↗
Dec 13, 2016 Trial start Phase 1/Phase 2: ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma source ↗
May 19, 2016 Trial start 2: Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) source ↗
Dec 8, 2014 Trial start Phase 3: BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis source ↗
2014-07 Trial start E: Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma source ↗
2013-11 Trial start Phase 3: ERADICATE Hp - Treating Helicobacter Pylori With RHB-105 source ↗
2013-09 Trial start Phase 3: Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease source ↗
2013-06 Trial start Phase 2: Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS) source ↗
2011-08 Trial start Phase 1: ABC294640 in Treating Patients With Advanced Solid Tumors source ↗

Funding

Raised: $4.0M. Last 2 years.

Oct 20, 2025 Private placement: $4M (total, as published), announced Oct 20, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 19

Record	Title	Phase	Status	Start	Primary completion
NCT04467840	Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia	Phase 2/Phase 3	Completed	Aug 21, 2020	Jul 18, 2021 (actual)
NCT03377179	A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma	Phase 2	Completed	Mar 7, 2018	Jun 21, 2022 (actual)
NCT04616924	RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease	Phase 3	Terminated	Dec 1, 2020	Aug 28, 2023 (actual)
NCT03414489	Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)	Not listed	No longer available	Not listed	Not listed
NCT04723537	Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease	Phase 2/Phase 3	Terminated	Feb 16, 2021	Dec 28, 2021 (actual)
NCT04027894	Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years	Phase 2	Unknown status (ClinicalTrials.gov)	2024-01	2025-01 (estimated)
NCT04026984	Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years	Phase 2	Unknown status (ClinicalTrials.gov)	2024-06	2025-06 (estimated)
NCT04414618	A Study of Opaganib in Coronavirus Disease 2019 Pneumonia	Phase 2	Completed	Jul 2, 2020	Nov 26, 2020 (actual)
NCT02757326	ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma	Phase 1/Phase 2	Terminated	Dec 13, 2016	2019-05 (actual)
NCT03009396	Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease	Phase 3	Completed	Mar 18, 2017	Nov 13, 2018 (actual)
NCT01951326	Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease	Phase 3	Completed	2013-09	2018-05 (actual)
NCT04502069	Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen	Phase 1/Phase 2	Withdrawn	2020-08	2021-02 (estimated)
NCT03198507	ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator	Phase 3	Completed	Jun 18, 2017	Oct 24, 2018 (actual)
NCT01488513	ABC294640 in Treating Patients With Advanced Solid Tumors	Phase 1	Completed	2011-08	2014-08 (actual)
NCT01980095	ERADICATE Hp - Treating Helicobacter Pylori With RHB-105	Phase 3	Completed	2013-11	2015-06 (actual)
NCT02246439	BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis	Phase 3	Completed	Dec 8, 2014	Feb 13, 2017 (actual)
NCT02757105	Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)	2	Completed	May 19, 2016	Jun 16, 2017 (actual)
NCT02229981	Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma	E	Withdrawn	2014-07	2019-06 (estimated)
NCT01717664	Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)	Phase 2	Completed	2013-06	2015-12 (actual)